Joshua Schimmer
Stock Analyst at Cantor Fitzgerald
(1.34)
# 3,387
Out of 4,761 analysts
25
Total ratings
52.94%
Success rate
-8.66%
Average return
Main Sectors:
Stocks Rated by Joshua Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CABA Cabaletta Bio | Reiterates: Overweight | $50 | $2.06 | +2,327.18% | 4 | Apr 5, 2024 | |
| MIRM Mirum Pharmaceuticals | Reiterates: Overweight | $50 | $52.45 | -4.67% | 2 | Nov 15, 2023 | |
| OTIS Otis Worldwide | Maintains: Equal-Weight | $91 → $92 | $98.37 | -6.48% | 4 | Jul 27, 2023 | |
| RNA Avidity Biosciences | Downgrades: In-Line | $20 | $31.12 | -35.73% | 1 | Mar 31, 2023 | |
| NBIX Neurocrine Biosciences | Upgrades: Outperform | $130 | $120.69 | +7.71% | 1 | Mar 3, 2023 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $80 → $50 | $20.73 | +141.20% | 1 | Feb 28, 2023 | |
| TGTX TG Therapeutics | Maintains: Outperform | $16 → $25 | $30.88 | -19.04% | 3 | Jan 24, 2023 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $65 → $75 | $10.47 | +616.33% | 1 | Sep 30, 2022 | |
| BMRN BioMarin Pharmaceutical | Upgrades: Outperform | $90 → $100 | $68.25 | +46.52% | 1 | Mar 1, 2021 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | n/a | $700.33 | - | 2 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $1,720 → $2,000 | $4.08 | +48,919.61% | 2 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $72.11 | +17.88% | 3 | May 31, 2018 |
Cabaletta Bio
Apr 5, 2024
Reiterates: Overweight
Price Target: $50
Current: $2.06
Upside: +2,327.18%
Mirum Pharmaceuticals
Nov 15, 2023
Reiterates: Overweight
Price Target: $50
Current: $52.45
Upside: -4.67%
Otis Worldwide
Jul 27, 2023
Maintains: Equal-Weight
Price Target: $91 → $92
Current: $98.37
Upside: -6.48%
Avidity Biosciences
Mar 31, 2023
Downgrades: In-Line
Price Target: $20
Current: $31.12
Upside: -35.73%
Neurocrine Biosciences
Mar 3, 2023
Upgrades: Outperform
Price Target: $130
Current: $120.69
Upside: +7.71%
Denali Therapeutics
Feb 28, 2023
Maintains: Outperform
Price Target: $80 → $50
Current: $20.73
Upside: +141.20%
TG Therapeutics
Jan 24, 2023
Maintains: Outperform
Price Target: $16 → $25
Current: $30.88
Upside: -19.04%
Rocket Pharmaceuticals
Sep 30, 2022
Maintains: Outperform
Price Target: $65 → $75
Current: $10.47
Upside: +616.33%
BioMarin Pharmaceutical
Mar 1, 2021
Upgrades: Outperform
Price Target: $90 → $100
Current: $68.25
Upside: +46.52%
Regeneron Pharmaceuticals
Feb 25, 2020
Upgrades: Outperform
Price Target: n/a
Current: $700.33
Upside: -
Feb 3, 2020
Upgrades: Outperform
Price Target: $1,720 → $2,000
Current: $4.08
Upside: +48,919.61%
May 31, 2018
Assumes: Overweight
Price Target: $85
Current: $72.11
Upside: +17.88%